Stock Comparison
GMAB vs REGN
Genmab AS and Regeneron Pharmaceuticals Inc side by side — valuation, profitability, growth and risk.
Valuation
Market Cap
$16.04B
$66.35B
P/E (TTM)
19.8
15.5
Forward P/E
15.6
14.1
Price/Sales
4.1
4.5
Price/Book
2.8
2.1
EV/EBITDA
15.3
10.5
Dividend Yield
—
0.58%
Profitability
Net Margin
21.00%
29.60%
Operating Margin
25.10%
20.70%
Return on Equity
15.00%
14.50%
Return on Assets
8.48%
6.13%
Growth (YoY)
Revenue Growth
25.30%
19.00%
Earnings Growth
-72.80%
-7.20%
Price & Risk
Beta
0.7
0.2
52-Week High
$35.43
$818.90
52-Week Low
$20.23
$516.07
Analyst Target
$36.82
$833.31
Compare GMAB and REGN your own way
Try mrmarket.ai freeFigures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.